The Risks of Assisting Evolution
By Elizabeth Alter,
The New York Times
| 11. 10. 2015
Untitled Document
THERE are four locked doors guarding a specialized lab at the Harvard School of Public Health. The doors are meant to prevent insects inside the lab from venturing out — which is essential, because researchers behind those doors are re-engineering mosquitoes by cutting and pasting bits of DNA with tools unimaginable a decade ago.
If researchers can figure out the right combination of genes, they’ll manufacture a mosquito resistant to malaria, which could save hundreds of thousands of lives every year. But geneticists, bioethicists and others who understand the implications of this new technology are apprehensive. To an astonishing degree, these new tools, which include a technique called Crispr-Cas9, allow us to bend evolution to our will. But will we harness these new technologies to help our planet? Or spark an ecological catastrophe?
In university labs, corporate R&D centers and even inside amateur D.I.Y. laboratories, researchers are creating genetically modified organisms at an unprecedented pace. This biotechnological revolution is so fast-moving that it hasn’t yet fully filtered into the public’s awareness or policy...
Related Articles
By Jonathan Matthews, GMWatch | 12.11.2025
In our first article in this series, we investigated the dark PR tactics that have accompanied Colossal Bioscience’s de-extinction disinformation campaign, in which transgenic cloned grey wolves have been showcased to the world as resurrected dire wolves – a...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...